The management of cardiac arrhythmias involves a wide range of antiarrhythmic drugs, with different pharmacokinetic and pharmacodynamic properties. Antiarrhythmic agents do not abolish the arrhythmia, but merely suppress the rhythm abnormality. The adverse effects associated with these drugs are very diverse in nature and severity — some are life-threatening. It is therefore important to balance the risks and benefits from arrhythmia treatment in individual patients.
Editor: R E Ferner, MSC, MD, FRCP, Director of the West Midlands Centre for Adverse Drug Reaction Reporting and Consultant Physician at City Hospital, Birmingham, UK. Consulting Editor: Professor D M Davies, FRCP, FRCP Ed. Assistant Editor: Mr C Anton, MA, MEng. Foreign Translation Editor: Mrs L Kelly, BA, ALA. Editorial Board: Australia: Dr M Kennedy, Professor G M Shenfield; Denmark: Professor J S Schou; England: Dr J K Aronson; Ireland: Professor J Feely; Netherlands: Professor C J van Boxtel, Dr B H Ch Stricker; New Zealand; Dr T Maling; Scotland: Dr D N Bateman; Sweden: Dr B-E Wiholm; Wales: Professor P A Routledge.
© 2000 Lippincott Williams & Wilkins, Inc.